Global Smart (AI) In-Vitro Diagnostics (IVD) Market Research Report 2023: Instrumentation, Automation and Diagnostic Trends - Decentralization and Point Of Care

Rhea-AI Summary

The Smart in Vitro Diagnostics report provides comprehensive insights into the AI IVD market, highlighting its growth driven by advancements in technology and demand for new testing regimes. Key developments include AI applications in diagnostics, with companies like Viome Life Sciences raising $67M for AI cancer diagnostics. The report outlines market trends such as decentralization and the role of bioinformatics, and forecasts demand in 18 countries. It also lists factors both driving and limiting growth in the sector, positioning stakeholders for strategic investments in this evolving market.

Positive

• Viome Life Sciences raises $67M in Series C financing for AI cancer diagnostics.
• Detailed report includes data for 18 countries and forecasts demand for new testing technologies.

Negative

• Challenges in growth include state of knowledge and regulatory coverage issues.

DUBLIN, March 10, 2023 /PRNewswire/ -- The "Smart in Vitro Diagnostics - Artificial Intelligence for IVD Markets by Application, by Technology and by User with Executive and Consultant Guides" report has been added to  ResearchAndMarkets.com's offering. 

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of United States Medicare Fee Payment Schedules to help understand the new pricing for nucleic acid based tests.

Will Smart Diagnostics replace the physician? Will the power of Artificial Intelligence provide better diagnostics? The market is moving out of a research mode into the clinic. The market is exploding as physicians use all the information they can get to battle disease. While Pharmaceutical Companies see the potential to make nearly any therapy viable. Find out how this new approach to diagnostics will change medical care forever.

Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of many diagnostics continues to fall.

Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

Recent Developments

• Vesale Bioscience to Develop AI Phage Therapy Diagnostic Platform
• Caris Life Sciences To Use AI and Machine Learning
• Numares Health To Develop AI for "Metabolite Constellations"
• Sepsis Testing Startup DeepUll to Use AI for Medical Decisions
• Viome Life Sciences Raises $67M in Series C Financing For AI Cancer Dx
• ADM Diagnostics Wins Grant for Brain Injury Test Development
• Paige to Develop New AI-based Pathology Test
• Aiforia Gains CE-IVD Mark for AI-Powered Histopathology
• Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
• Thermo Fisher Introduces Homologous Score for Cancer Profiling
• Genomic Test IDs Cancer Cells Early
• Caris Life Sciences to Offer Molecular Profiling Services
• Geneseeq to Build Lab for Cancer Profiling in Brazil
• Genetron Health Adds New Assays to Pipeline
• Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
• Guardant Health Receives Medicare Coverage for Guardant360 TissueNextT Test
• Labcorp, CCORN Partner for Precision Oncology
• Dante Labs Acquires Cambridge Cancer Genomics
• Celemics, Strand Partner on Integrated Platform for NGS Analysis
• Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
• Burning Rock Revenues Rise
• Caris Life Sciences to Expand Liquid Biopsy Testing
• OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
• Intermountain and Myriad Combine Test Offering
• Illumina, Geneseeq to Offer Cancer Testing Kits in China
• Exact Sciences to Offer End-to-End Cancer Testing
• Guardant Health Turns to Tumor Tissue Sequencing
• Tempus Inks Oncology Testing Collaboration With Bayer
• Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
• Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
• Metastatic Cancer Markers Identified in Clinical WGS Study
• Stitch Bio Bets on CRISPR Tech
• Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
• Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
• Progress, Challenges in Liquid Biopsy Reimbursement
• Israeli Startup Curesponse Raises $6M
• Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
• MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
• NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
• Germline Results Guides Precision Therapy in Advanced Cancer
• FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
• ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
• Labs Reporting Cancer Risk Mutations from Tumor Testing
• Users Begin Integrating Genomics Data for Clinical Decision Support
• Fujitsu Improves Efficiency in Cancer Genomic Medicine

Market Trends

Factors Driving Growth

• Level of Care
• Companion Dx
• Immuno-oncology
• Liability
• The Aging Effect

Factors Limiting Growth

• State of knowledge
• Genetic Blizzard
• Protocol Resistance
• Regulation and coverage

Instrumentation, Automation and Diagnostic Trends

• Traditional Automation and Centralization
• The New Automation, Decentralization and Point Of Care
• Instruments Key to Market Share
• Bioinformatics Plays a Role
• PCR Takes Command
• Next Generation Sequencing Fuels a Revolution
• NGS Impact on Pricing
• Whole Genome Sequencing, A Brave New World
• Companion Diagnostics Blurs Diagnosis and Treatment
• Shifting Role of Diagnostics

Market Overview

Players in a Dynamic Market

• Academic Research Lab
• Diagnostic Test Developer
• Instrumentation Supplier
• Chemical/Reagent Supplier
• Pathology Supplier
• Independent Clinical Laboratory
• Public National/regional Laboratory
• Hospital Laboratory
• Physicians Office Lab (POLS)
• Audit Body
• Certification Body

Oncogenomics

• Carcinogenesis
• Chromosomes, Genes and Epigenetics
• Chromosomes
• Genes
• Epigenetics
• Cancer Genes
• Germline vs Somatic
• Gene Panels, Single Gene Assays and Multiplexing
• Genomic Profiling
• The Comprehensive Assay
• Changing Clinical Role
• The Cancer Screening Market Opportunity

Cancer Management vs. Diagnosis

• The Role of Risk Assessment
• Diagnosis
• Managing
• Monitoring

Phases of Adoption - Looking into The Future

Structure of Industry Plays a Part

• Hospital Testing Share
• Economies of Scale
• Hospital vs. Central Lab
• Physician Office Lab's
• Physician's and POCT

Profiles of Key Players

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Aethlon Medical
• Agilent/Dako
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• BGI Genomics Co. Ltd
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bolidics
• Boreal Genomics
• Bristol-Myers Squibb
• Burning Rock
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• Celemics
• CellMax Life
• Cepheid (Danaher)
• Charles River Laboratories
• Circulogene
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Exact Sciences
• Fabric Genomics
• Fluxion Biosciences
• Freenome
• FUJIFILM Wako Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HeiScreen
• Helomics
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• Integrated Diagnostics
• Invitae Corporation
• Invivogen
• Invivoscribe
• Janssen Diagnostics
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics/Myriad RBM
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene Bioinformatics Technology Co., Ltd.
• Oncocyte
• OncoDNA
• Ortho Clinical Diagnostics
• Oxford Nanopore Technologies
• Panagene
• Perkin Elmer
• Personal Genome Diagnostics
• Personalis
• Precipio
• Precision Medicine Group
• PrecisionMed
• Promega
• Qiagen
• Rarecells SAS
• RareCyte
• Roche Molecular Diagnostics
• Screencell
• Sense Biodetection
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific Inc.
• Todos Medical
• Ultima Genomics
• Variantyx
• Veracyte
• Volition
• Vortex Biosciences
• Vyant Bio
• Singular Genomics
• SkylineDx
• Standard BioTools
• Sure Genomics, Inc.
• Sysmex
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific Inc.
• Ultima Genomics
• Variantyx
• Volition

For more information about this report visit https://www.researchandmarkets.com/r/a7dcxm-in-vitro?w=5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-smart-ai-in-vitro-diagnostics-ivd-market-research-report-2023-instrumentation-automation-and-diagnostic-trends---decentralization-and-point-of-care-301768826.html

SOURCE Research and Markets

FAQ

What does the Smart in Vitro Diagnostics report cover?

The report covers AI applications in in-vitro diagnostics, market trends, and forecasts for demand in 18 countries.

Who raised $67 million for AI cancer diagnostics?

Viome Life Sciences raised $67 million in Series C financing for AI cancer diagnostics.

What are the factors limiting the growth of the AI IVD market?

Factors limiting growth include state of knowledge and regulatory coverage issues.

How does the Smart in Vitro Diagnostics report benefit stakeholders?

It provides data and forecasts to help stakeholders make informed investment decisions in the evolving IVD market.

What trends are shaping the AI IVD market?

Key trends include decentralization, advancements in bioinformatics, and the integration of AI into diagnostics.